BCRX Trademark

Trademark Overview

On Thursday, June 17, 2021, a trademark application was filed for BCRX with the United States Patent and Trademark Office. The USPTO has given the BCRX trademark a serial number of 90780437. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Friday, May 24, 2024. This trademark is owned by BioCryst Pharmaceuticals, Inc.. The BCRX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research services; pharmaceutical drug development services; medical and scientific research, namely, conducting clinical trials for others; development of pharmaceutical preparations and medicines for the treatment of infectious, viral, inflammatory, immunological, autoimmune, and cardiovascular diseases and disorders; development of pharmaceutical preparations and medicines for the treatment of cancer, namely, cancers of the immune system, namely, T-cell and B-cell leukemias and lymphomas; development of pharmaceutical preparations and medicines for the treatment of influenza, AIDS, SARS, Ebola, Zika, and West Nile virus; development of pharmaceutical preparations and medicines for the treatment of hereditary angioedema, inflammatory bowel diseases, inflammatory connective tissue diseases, and inflammatory skin diseases
bcrx

General Information

Serial Number90780437
Word MarkBCRX
Filing DateThursday, June 17, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateFriday, May 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 26, 2022

Trademark Statements

Goods and ServicesPharmaceutical research services; pharmaceutical drug development services; medical and scientific research, namely, conducting clinical trials for others; development of pharmaceutical preparations and medicines for the treatment of infectious, viral, inflammatory, immunological, autoimmune, and cardiovascular diseases and disorders; development of pharmaceutical preparations and medicines for the treatment of cancer, namely, cancers of the immune system, namely, T-cell and B-cell leukemias and lymphomas; development of pharmaceutical preparations and medicines for the treatment of influenza, AIDS, SARS, Ebola, Zika, and West Nile virus; development of pharmaceutical preparations and medicines for the treatment of hereditary angioedema, inflammatory bowel diseases, inflammatory connective tissue diseases, and inflammatory skin diseases

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 3, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBioCryst Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDurham, NC 27703
Party NameBioCryst Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDurham, NC 27703

Trademark Events

Event DateEvent Description
Wednesday, December 15, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, June 21, 2021NEW APPLICATION ENTERED
Friday, September 3, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, December 15, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, December 15, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, December 22, 2021TEAS VOLUNTARY AMENDMENT RECEIVED
Monday, December 27, 2021ASSIGNED TO LIE
Wednesday, December 29, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, December 29, 2021PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Monday, March 14, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, March 8, 2022ASSIGNED TO EXAMINER
Monday, March 14, 2022EXAMINERS AMENDMENT -WRITTEN
Monday, March 14, 2022EXAMINERS AMENDMENT E-MAILED
Monday, March 14, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, March 23, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 6, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 26, 2022PUBLISHED FOR OPPOSITION
Tuesday, April 26, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 21, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 6, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, December 6, 2022SOU EXTENSION 1 FILED
Tuesday, December 6, 2022SOU EXTENSION 1 GRANTED
Thursday, December 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 20, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, June 20, 2023SOU EXTENSION 2 FILED
Tuesday, June 20, 2023SOU EXTENSION 2 GRANTED
Thursday, June 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 24, 2024SOU TEAS EXTENSION RECEIVED
Friday, May 24, 2024SOU EXTENSION 4 GRANTED
Friday, May 24, 2024SOU EXTENSION 4 FILED
Tuesday, November 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 17, 2023SOU TEAS EXTENSION RECEIVED
Friday, November 17, 2023SOU EXTENSION 3 FILED
Friday, November 17, 2023SOU EXTENSION 3 GRANTED

Related Keywords

bcrx pharmaceutical development medicines inflammatory preparations treatment diseases namely services cell